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Chang, Wu, Lee, Shih (left to right)doi:10.1016/j.jtcvs.2005.06.012Objective: Estrogen receptor expression in lung cancer has been understudied,
particularly in light of its potential biologic importance in the epidemic of lung
cancer in women. The expression of estrogen receptors was investigated to better
understand the possible role of sex hormones in lung cancer.
Methods: A total of 301 patients with surgically resected non–small cell lung
cancers of stages I to III were explored. Sections of paraffin-embedded tumor
samples were stained with estrogen receptor  and estrogen receptor  antibodies.
Tumors with moderate-to-strong nuclear staining in at least 50% of the tumor cells
were scored as positive for overexpression.
Results: The overall frequency of overexpression for estrogen receptor  was 45.8%
(138/301). It was detected most frequently in female patients (in 54.3% of 127
tumors vs 39.7% of 174 tumors in men, P  .012). However, there was no estrogen
receptor  nuclear staining detectable in non–small cell lung cancers. Interestingly,
a significant correlation between estrogen receptor  expression, stage of disease,
grade of differentiation, smoking status, vascular invasion, and survival in patients
with stage II and III disease was found. By using multivariate analysis of survival
among patients with stage II and III disease, estrogen receptor  overexpression,
stage II tumor, well differentiation, nonsmoking status, and lack of vascular inva-
sion were significantly favorable prognostic factors.
Conclusions: The results presented here show for the first time that immunohisto-
chemical expression of estrogen receptor  can be used as a prognostic indicator in
patients with surgically resected stage II and III non–small cell lung cancers. These
observations might offer a possibility for hormonal therapy in patients with lung
cancer.
Lung cancer is one of the leading causes of cancer death in Taiwan1 and themost common cause of cancer death in Western countries.2 With the 5-yearsurvival rate at only about 10%, lung cancer causes more than 6000 deaths
per year in Taiwan. The majority of these tumors are non–small cell lung carcino-
mas (NSCLCs), of which adenocarcinoma is the most common histologic type.3,4
Although cigarette smoking is the major risk factor, most people who smoke do
not have lung cancer. Only approximately 3% of lung cancers occurred in non-
smokers5 in the Western world, and the majority of female patients with lung cancer
were nonsmokers in Taiwan.6 Therefore factors other than cigarette smoking must
also have a role in the pathogenesis of lung cancer. Such factors might be environ-
mental (water and air pollution or occupational exposure) or host related (genetic or
nutritional).
Sex hormones might be a host-related factor that influences the development of
lung cancer in men and women. Estrogen receptors (ERs) are normally found in the
breast and tissues of the female reproductive tract. Additionally, they are sometimes
found in the neoplasms of these tissues.7 The existence of ERs has also been
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ningiomas and primary brain tumors, malignant melanomas,
sarcomas, carcinomas of the head and neck, thyroid gland,
lungs, liver, pancreas, stomach, colon, and prostate gland.8
The human ER, now termed ER, was first cloned in 1986.
For the next 10 years, research on its ligand-dependent effects
focused on the binding of estrogen to one cognate receptor.9
In 1996, a second isoform of ER, referred to as ER, was
discovered, which redefined concepts of the estrogen sig-
naling pathway.10 The ER protein has similarities to the
classical ER in terms of structure and function. The tissue
distribution of these 2 receptors is not identical, but it appears
to overlap in some cases.11 ER and ER also differ in their
effect on transcription at activator protein-1 (AP-1) sites.12
Whereas ER as a ligand to estradiol activates transcription
at AP-1 sites, ER as a ligand to estradiol inhibits transcrip-
tion at AP-1 sites. This evidence suggests that ER and
ER might be regulated by distinct mechanisms and play
different roles in gene regulation, although sharing func-
tional characteristics. Thus far, only limited data are avail-
able on the activity and expression of ERs in human lung
neoplasms. Because there have been conflicting results in
the literature, possibly as a result of the small number of
tumors studied, the role of ERs has remained obscure.8,13-19
The evolution from nonselective methods of detection of
ERs (biochemical assay) to a more reliable method making
use of monoclonal antibodies (immunohistochemical assay)
has allowed the identification of the receptors in their func-
tional site, the nucleus. The immunohistochemical assay is
more selective and specific because of the use of monoclo-
nal antibodies reacting with epitopes that offer only minimal
variability. In the present study, the expression of ER and
ER, as determined by means of immunohistochemistry, in
301 surgically resected NSCLCs was investigated. These
findings were correlated with the clinicopathologic features,
including sex, smoking history, histologic type and differ-
entiation, tumor size, stage, vascular invasion, lymph node
metastasis, and survival.
Materials and Methods
Patients and Tumor Specimen
Three hundred one NSCLC specimens were obtained from patients
who underwent complete surgical resection at National Taiwan
University hospital between January 1990 and December 2001.
The study was approved by the Research Ethics Committee of this
hospital. These patients were not treated with neoadjuvant chemo-
therapy and irradiation therapy. All specimens were formalin fixed
and sectioned for microscopic examination after applying hema-
toxylin and eosin stain. Histologic diagnosis and pathologic fea-
tures were obtained, including tumor cell type, degree of differ-
entiation, vascular invasion, and regional lymph node metastasis.
Pathologic staging was performed according to the international
staging system for lung cancer,20 which was based on tumor size,
location and involvement, and the presence of lymph node metas-
tasis. Adenosquamous carcinomas were not included in the clas-
980 The Journal of Thoracic and Cardiovascular Surgery ● Octosification of histologic type and grade of differentiation because of
the discrepancy in each tumor. The patient numbers in some
parameters might be less because the information was not avail-
able in a few cases. The women were grouped into 2 categories on
the basis of the average US menopausal age of 51 years, as defined
by the American College of Obstetricians and Gynecologists.
Premenopausal was defined as women aged less than 51 years and
postmenopausal was defined as women aged at least 51 years.21
The follow-up period ranged from 2 to 168 months (median
survival, 41 months).
Immunohistochemistry
For immunohistochemical demonstration of ER or ER expres-
sion in the tumor tissue, 4-m-thick sections from each formalin-
fixed, paraffin-embedded tissue block were dewaxed with xylene
and rehydrated through a graded series of ethanol.
The sections for immunohistochemistry of the ER and ER
expression were autoclaved in 0.01 mol/L citrate buffer (pH 6.0) at
121°C for 10 minutes (ER) and in EDTA buffer (pH 8.0) for 8
minutes (ER). They were treated with 3% H2O2-methanol solu-
tion to reduce endogenous peroxidase activity. These were then
incubated with normal goat serum to reduce nonspecific antibody
binding and were subsequently subjected to the primary antibody
reaction. The antibodies for ER (1:100, BioGenex) and ER
(1:30, BioGenex) were left to react with the sections overnight
(ER) and for 2 hours (ER) at room temperature. Detection of the
immunoreactive staining was carried out by using the avidin-biotin-
peroxidase complex method, according to the manufacturer’s instruc-
tions (Dako Corp). The primary antibody was replaced with bovine
serum albumin to check for nonspecific staining by the avidin-biotin-
peroxidase complex detection system. The sections were then sub-
jected to a color reaction with 0.05% 3,3-diaminobenzidine in 0.05
mol/L Tris base (pH 7.6) containing 0.01% H2O2 and were lightly
counterstained with hematoxylin.
Assessment of ER Expression
By using an infiltrating ductal carcinoma of the breast with a high
content of ER and ER as a positive control, the expression of
ER and ER for each tumor was assessed. Tumors were consid-
ered to be positive when there was moderate-to-strong nuclear
staining of more than 50% of the neoplastic cells. Two indepen-
dent pathologists (C-TW and Y-LC) were involved in the assess-
ment of expression.
Statistical Analysis
The correlation between various clinical or pathologic parameters
and the expression of ER was analyzed by using the Pearson 2
test. Survival curves were estimated by using the Kaplan-Meier
method. The log-rank test was used to compare survival curves.
Cox proportional hazards regression was used to model survival
with ER overexpression and clinicopathologic variables typically
associated with prognosis. The following factors were modeled in
a univariate fashion: sex (male or female); histologic type (squa-
mous cell carcinomas or bronchioloalveolar carcinomas and ade-
nocarcinomas); tumor size (3 cm or 3 cm); stage (I, II, and III);
grade of differentiation (well, moderately, or poorly differenti-
ated); smoking status (smokers or nonsmokers); vascular invasion
(absent or present); and ER overexpression (positive or negative).
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with those variables that demonstrated statistical significance (P
.050) in the univariate models. SPSS version 10.0 software (SPSS
Inc) was used for all analyses.
Results
Patient Demographics
Of the 301 patients in this study, 174 were men, and 127
were women. Their ages ranged from 30 to 83 years, with a
mean age of 63 years. All patients underwent complete
surgical resection with regional lymph node dissection.
The majority of the male patients were smokers (120/164
[73.2%]), whereas the majority of the female patients were
nonsmokers (115/126 [91.3%], P  .001). There were 90
squamous cell carcinomas, 194 adenocarcinomas, and 17
adenosquamous carcinomas. Among patients with squa-
mous cell carcinomas, most of the male patients were smok-
ers (65/72 [90.3%]), whereas the female patients were pre-
dominantly nonsmokers (9/13 [69.2%], P  .001). Among
patients with adenocarcinomas, most of the male patients
were smokers (49/80 [61.3%]), and 101 (93.5%) of 108
female patients were nonsmokers. This difference was also
statistically significant (P  .001, Table 1).
Correlations Between ER Expression and
Clinicopathologic Features
In the current study, ER nuclear reactivity was detected in
138 (45.8%) of the 301 lung cancers, usually of moderate-
to-strong intensity. The remaining 163 (54.2%) lung cancers
were characterized by complete absence of nuclear staining
or 50% or less immunoreactivity. The relationship between
TABLE 1. Relationship between patient demographics and
Parameters
No. of
patients
No. of p
smoki
Total patients 301
Sex
Male 174
Female 127
Histologic type
Squamous cell carcinoma 90
Male 77
Female 13
Adenocarcinoma 194
Male 85
Female 109
Adenosquamous carcinoma 17
Male 12
Female 5
Age (y)
50 41
50 260clinical parameters or pathologic characteristics and the
The Journal of Thoracifrequency of ER reactivity is shown in Table 2. Higher
ER expression was noted in female patients, nonsmokers,
patients with tumors of 3 cm or smaller, patients without
lymph node metastasis, and patients with tumors with a
lower grade of differentiation.
Overexpression of ER was significantly more common
in tumors occurring in nonsmokers (53.5%) than in those of
smokers (36.6%, P .004). Among the nonsmokers, higher
ER expression was observed more frequently in female
patients (58.3%) than in male patients (40.9%), and such a
difference was also statistically significant (P  .050). In
both squamous cell carcinoma and adenocarcinoma (includ-
ing bronchioloalveolar carcinoma), the overexpression of
ER was observed preferentially in well-differentiated sub-
types (P  .001).
Differences in ER expression were not statistically sig-
nificant (P  .579) between the premenopausal and post-
menopausal groups of female patients.
Correlations Between ER Expression,
Clinicopathologic Features, and Survival
The influence of various clinicopathologic parameters on
overall patient survival was analyzed (Table 3). By using
univariate analysis of survival, significantly better prognos-
tic indicators included tumors of 3 cm or smaller, early-
stage tumors, tumors with a lower grade of differentiation,
tumors without vascular invasion, and increased levels of
ER expression. By using multivariate analysis, early-stage
tumors, tumors with a lower grade of differentiation, and
tumors without vascular invasion remained as statistically
king history
ts with
story
Smokers
(%)
Nonsmokers
(%) P value
120 (73.2) 44 (26.8)
11 (8.7) 115 (91.3) .001
65 (90.3) 7 (9.7)
4 (30.8) 9 (69.2) .001
49 (61.3) 31 (38.8)
7 (6.5) 101 (93.5) .001
6 (50) 6 (50)
0 (0) 5 (100) .049
12 (31.6) 26 (68.4)
119 (47.2) 133 (52.8) .071smo
atien
ng hi
164
126
72
13
80
108
12
5
38significant prognostic factors indicating better survival.
c and Cardiovascular Surgery ● Volume 130, Number 4 981
not
General Thoracic Surgery Wu et al
G
TSThese patients were then divided according to their tumor
stage. In patients with stage I disease, there were no signif-
icant prognostic indicators, including ER overexpression,
determined by using univariate analysis of survival. A total
of 187 patients had stage II and III tumors. An analysis of
the effect of various clinicopathologic factors on patient
survival was performed for these patients with stage II and
III disease (Table 4). By using univariate analysis, stage II
tumors, tumors with a lower grade of differentiation, non-
smoking status, tumors without vascular invasion, and in-
creased expression of ER were found to be significantly
better prognostic indicators. By using multivariate analysis,
all 5 factors remained statistically significant favorable
prognostic indicators (Figure 1).
ER Expression
In contrast, there was no ER nuclear staining in any
NSCLCs. Only 8 cases demonstrated cytoplasmic staining.
TABLE 2. Frequency of ER expression with relation to c
Parameters No. of patients*
Patient no. 301
Menopausal age (y)
50 (premenopausal) 20
50 (postmenopausal) 107
Sex
Male 174
Female 127
Smoking history
Positive 131
Negative 159
Histologic type†
Squamous cell carcinoma 90
Adenocarcinoma 194
Tumor size
3 cm 127
3 cm 174
Tumor stage
I 114
II 67
III 120
Vacular invasion
Positive 70
Negative 231
Lymph node metastasis
Positive 168
Negative 133
Grade of differentiation†
Well 106
Moderate 149
Poor 29
*Some of the patients lack information. †Adenosquamous carcinomas areThe staining intensity of most cases was weak.
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The presence of ERs in human lung cancers has been
controversial for many years. Some studies have been per-
formed to assess the expression of ERs in human lung
cancers to explain sex differences in incidence, histology,
and prognosis of human NSCLCs between female and male
patients.5,8,13,14,22 However, reported values have varied
widely, and the involvement of this receptor in lung phys-
iology, pathology, or both remains unclear.
ERs, members of the nuclear steroid receptor superfam-
ily, mediate cellular response to estrogen. Two ERs have
been identified, ER and ER, which are encoded by sep-
arate genes. ER is localized on human chromosome 14,
whereas ER is located on chromosome 6.23 These proteins
function as sequence-specific, ligand-activated transcription
factors. Both receptors possess several distinct functional
domains, including a central DNA-binding domain that is
highly conserved between ER and ER.24 These func-
al parameters and pathologic characteristics
ER >50% (%) ER <50% (%) P value
138 (45.8) 163 (54.2)
12 (60.0) 8 (40.0) .579
57 (53.3) 50 (46.7)
69 (39.7) 105 (60.3) .012
69 (54.3) 58 (45.7)
48 (36.6) 83 (63.4) .004
85 (53.5) 74 (46.5)
37 (41.1) 53 (58.9) .163
97 (50.0) 97 (50.0)
68 (53.5) 59 (46.5) .022
70 (40.2) 104 (59.8)
61 (53.5) 53 (46.5) .112
27 (40.3) 40 (59.7)
50 (41.7) 70 (58.3)
34 (48.6) 36 (51.4) .602
104 (45.0) 127 (55.0)
66 (39.3) 102 (60.7) .010
72 (54.1) 61 (45.9)
66 (62.3) 40 (37.7) .001
59 (39.6) 90 (60.4)
9 (31.0) 20 (69.0)
included.linictional differences could be due to the dissimilarities in
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interact with different sets of proteins. The tissue distri-
bution of ER is also different from that of ER, sug-
gesting that these proteins function in a tissue-specific
manner.11
ER has been shown to be expressed and functional in
most human NSCLC cell lines and cells derived from nor-
mal lung and tissues.2,18,19 Most investigations have been
performed at the mRNA expression level with reverse
transcriptase–polymerase chain reaction analysis; how-
ever, very few studies have applied immunohistochemis-
try.25 In the present study a positive correlation between
ER protein overexpression and female sex, nonsmoking
status, tumors of 3 cm or smaller, absence of lymph node
metastasis, and tumors with a lower grade of differentiation
was noted. We found positive ER expression in squamous
cell carcinomas and adenocarcinomas. Although it has been
recognized that ER expression is found to be higher in
tumors from women15 and adenocarcinomas,18 other au-
thors have also reported positive ER expressions in both
TABLE 3. Correlations between ER expression, clinicopa
I to III disease
Variables
No. of
patients*
No. of
deaths
Hazard
ratio
ER overexpression
Negative 163 84 1.000
Positive 138 55 0.672
Size
3 cm 127 48 1.000
3 cm 174 91 1.776
Stage
I 114 21 1.000
II 67 33 3.635
III 120 85 6.870
Differentiation†
Well 106 35 1.000
Moderate 149 75 1.984
Poor 29 19 3.229
Vascular invasion
Negative 231 93 1.000
Positive 70 46 2.355
Sex
Female 127 52 1.000
Male 174 87 1.387
Smoking history
Negative 159 66 1.000
Positive 131 66 1.403
Histologic type†
Squamous cell carcinoma 90 45 1.000
Adenocarcinoma 194 84 0.778
*Some of the patients lack information. †Adenosquamous carcinomas aresquamous cell carcinomas and adenocarcinomas.22,26,27
The Journal of ThoraciBronchogenic carcinomas of all major cell types are
thought to arise from a common precursor cell and share
certain genetic abnormalities (ie, deletions or rearrange-
ments of the short arm of chromosome 3).28 Therefore it
is not surprising that lung cancers of different cell types
share a property like positive sex hormone receptor
status.
The correlation between ER and various clinicopatho-
logic factors has revealed that ER is expressed predomi-
nantly in well-differentiated and small-sized lung cancers.
This result indicates that the expression of ER is lost
during dedifferentiation of the tumor cells. It is also noted
that ER is tightly associated with lymph node status. This
suggests that the loss of ER expression might be an indi-
cator of a tumor phenotype with high metastatic potential.
Such a role is in agreement with the findings of metastatic
tendency in the axillary lymph nodes of breast cancers.29
This implies that ER might play a gatekeeper role by
inhibiting invasion and proliferation and maintaining the
low biologic aggressiveness and might be related to sup-
ogic features, and survival in 301 patients with stage
Univariate Multivariate
95% CI P value
Hazard
ratio 95% CI P value
1.000
0.478-0.945 .022 0.719 0.504-1.026 .069
1.248-2.526 .001
1.000
2.082-6.349 .001 3.084 1.732-5.489 .001
4.201-11.236 .001 6.021 3.577-10.136 .001
1.000
1.322-2.977 .001 1.372 0.906-2.079 .136
1.837-5.676 .001 2.895 1.630-5.142 .001
1.000
1.644-3.373 .001 1.749 1.186-2.580 .005
0.983-1.958 .063
0.997-1.974 .052
0.539-1.121 .177
included.tholpression of tumor growth.30
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stage II tumors, a lower grade of differentiation, nonsmok-
ing status, tumors without vascular invasion, and overex-
pression of ER have a better clinical prognosis among
patients with stage II and III disease. The meaning of this
association is not clear and has never been reported before.
However, our unexpected findings suggest that estrogens
might be involved in lung carcinogenesis, probably either
by acting as ER ligands and activating cell-proliferation
pathways or by metabolic activation to reactive intermedi-
ates that can produce DNA adducts or cause oxidation
damage, as mentioned in a recent study.31
Adenocarcinoma of the lung, which shows a weaker
association with tobacco smoking than with other types of
lung cancer, is also found predominantly in women, sug-
gesting a possible role for female hormones in this form of
disease.32,33 In our study the distribution of hormone recep-
tors in NSCLCs also appeared in male patients. This phe-
nomenon might be partly explained by the fact that estrogen
could have a role in cancer in male patients. Because the
enzyme aromatase (CYP19), which is expressed in many
TABLE 4. Correlations between ER expression, clinicopa
III disease
Variables
No. of
patients*
No. of
deaths
Hazard
ratio
ER overexpression
Negative 110 77 1.000
Positive 77 41 0.581
Stage
II 67 33 1.000
III 120 85 1.880
Differentiation†
Well 53 28 1.000
Moderate 102 65 1.523
Poor 21 16 2.697
Smoking status
Nonsmokers 98 57 1.000
Smokers 82 57 1.651
Vascular invasion
Negative 131 75 1.000
Positive 56 43 1.830
Sex
Female 76 45 1.000
Male 111 73 1.384
Histologic type†
Squamous cell carcinoma 58 36 1.000
Adenocarcinoma 118 73 0.876
Size
3 cm 53 32 1.000
3 cm 134 86 1.307
*Some of the patients lack information. †Adenosquamous carcinomas aretissues outside the reproductive tract, is able to convert
984 The Journal of Thoracic and Cardiovascular Surgery ● Octoandrogen to estrogen,31,34 local tissue production of estro-
gen might also occur in male patients. These results indicate
that blocking the effects of estrogen might be an important
therapeutic strategy to halt lung cancer progression or pre-
vent recurrence in patients of both sexes.
From an endocrinologic point of view, the expression of
ER has been noted as more common in premenopausal and
perimenopausal patients with cancer than in postmeno-
pausal patients with breast cancer.29 In one recent study
examining a large multi-institutional database, premeno-
pausal women were found to have more advanced lung
cancer and to undergo more extensive resection, yet these
women had a survival advantage compared with postmeno-
pausal women.21 However, ER status in these patients’
tumors was not examined. In this study we did not find a
concordance between menopause status and ER overex-
pression in NSCLCs.
Our results unequivocally demonstrate that ER can be
routinely detected in archival, formalin-fixed, and paraffin-
embedded lung cancers by using the monoclonal antibody.
This could have profound clinical implications because the
gic features, and survival in 187 patients with stage II and
Univariate Multivariate
95% CI P value
Hazard
ratio 95% CI P value
1.000
0.397-0.849 .005 0.662 0.439-0.999 .049
1.000
1.251-2.823 .002 2.081 1.304-3.321 .002
1.000
0.977-2.374 .063 1.183 0.745-1.878 .476
1.452-5.007 .002 2.233 1.158-4.305 .016
1.000
1.142-2.387 .008 1.762 1.168-2.659 .007
1.000
1.248-2.684 .002 1.639 1.079-2.490 .021
0.954-2.007 .087
0.587-1.308 .518
0.870-1.964 .197
included.thololevel of sex hormone receptors in cancer tissue often is
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treatment. The finding of ER in a wide array of nontarget
neoplastic tissues might be indicative of their common role
in the regulation of cancer growth, irrespective of the organ
involved.
On the basis of immunohistochemistry results, the forms
of ER expressed in our lung cancer tissues were located
primarily in the cytoplasm, and the cases were few. The
reason might be that lung cancer cells have little or no
full-length ER and that the stained variant is mainly cy-
toplasmic.19 According to several recent reports, immuno-
histochemical study also failed to demonstrate ER nuclear
expression in lung cancers.17,18 The reasons for this finding
remain unclear.
In conclusion, this study is the first to demonstrate the
association between ER overexpression and female sex,
nonsmoking status, tumors of 3 cm or smaller, absence of
lymph node metastasis, and tumors with a lower grade of
differentiation in a large cohort of patients with NSCLCs by
means of immunohistochemistry. Interestingly, the present
results also have clinical implications because of the obser-
vation of a statistically significant correlation between sur-
vival and tumors with stage II diseases, a lower grade of
differentiation, nonsmoking status, tumors without vascular
invasion, and increased expression of ER in stage II and III
NSCLCs. Thus it is strongly indicated that ER overexpres-
sion could be a useful and statistically significant prognostic
Figure 1. Survival curves in patients with stage II and III disease:
surgically resected non–small cell lung carcinomas with positive
(>50%) or negative (<50%) estrogen receptor  expression (P 
.004, log-rank test). ER, Estrogen receptor.marker for surgically resected stage II and III NSCLCs.
The Journal of ThoraciThese studies might also provide the possibility for a new
type of adjuvant therapy in selected patients with lung
cancer.
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